About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


The ConcePTION Meds4Mums2B [Meds for mums to be] app, developed in partnership with the UK regulatory agency MHRA, will launch in the United Kingdom in spring 2024. It is the first of its kind, and will help share and collect vital safety information about medicine use during pregnancy and breastfeeding. With this dual mission, the app will help change how we approach healthcare for expectant and nursing mothers.  | READ MORE >>
From 6 to 12 November, ConcePTION will take part in the global #MedSafetyWeek campaign, a collaboration involving more than 80 medicines regulatory agencies and several non-governmental organisations, to raise awareness about the importance of reporting side effects of medicines. And for pregnant women to report every time they are exposed to a medicine, to help close the knowledge gap in medicine safety for pregnancy and lactation. With the theme ‘Who can report?’, this year’s campaign will focus on the key role of every patient, woman, doctor, nurse, and pharmacist who reports a side effect or exposure and contributes to safe medicine use.  | READ MORE >>
There is a growing number of human data catalogues. As the European Health Data Space (EHDS) is developing it vision for a joint European descriptive metadata catalogue to help enable secondary use of the data in these catalogues, the experience of developing the ConcePTION data catalogue can be of great relevance. A recent opinion review shares several recommendations on what is needed to make human data catalogues work better together. | READ MORE >>

Twitter / X

the availability of physiological data in infants for PBPK modelling can be improved by systematic searches, as the physiology of a breastfed is different from a formula fed infant. Relevant for lactation-related drug exposure. https://www.mdpi.com/1999-4923/15/11/2618. IMI Conception.

JUST PUBLISHED: Challenges Related to Acquisition of Physiological Data for Physiologically Based Pharmacokinetic (PBPK) Models in Postpartum, Lactating Women and Breastfed Infants—A Contribution from the ConcePTION Project 👇

Connect with us!

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.